Premium
COVID ‐19 end‐of‐life care: symptoms and supportive therapy use in an Australian hospital
Author(s) -
Wong Aaron K.,
Demediuk Lucy,
Tay Jia Y.,
Wawryk Olivia,
Collins Anna,
Everitt Rachel,
Philip Jennifer,
Buising Kirsty,
Le Brian
Publication year - 2021
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.15300
Subject(s) - medicine , interquartile range , end of life care , cohort , palliative care , retrospective cohort study , referral , psychological intervention , covid-19 , cohort study , emergency medicine , comorbidity , pediatrics , family medicine , disease , psychiatry , nursing , infectious disease (medical specialty)
Background Descriptions of symptoms and medication use at end of life in COVID‐19 are limited to small cross‐sectional studies, with no Australian longitudinal data. Aims To describe end‐of‐life symptoms and care needs of people dying of COVID‐19. Methods This retrospective cohort study included consecutive admitted patients who died at a Victorian tertiary referral hospital from 1 January to 30 September directly due to COVID‐19. Clinical characteristics, symptoms and use of supportive therapies, including medications and non‐pharmacological interventions in the last 3 days of life were extracted. Results The cohort comprised 58 patients (median age 87 years, interquartile range (IQR) 81–90) predominantly admitted from home ( n = 30), who died after a median of 11 days (IQR 6–28) in the acute medical ( n = 31) or aged care ( n = 27) wards of the hospital. The median Charlson Comorbidity Score was 7 (IQR 5–8). Breathlessness ( n = 42), agitation ( n = 36) and pain ( n = 33) were the most frequent clinician‐reported symptoms in the final 3 days of life, with most requiring opioids ( n = 52), midazolam ( n = 40), with dose escalation commonly being required. While oxygen therapy was commonly used ( n = 47), few ( n = 13) required an anti‐secretory agent. Conclusions This study presents one of the first and largest Australian report of the end of life and symptom experience of people dying of COVID‐19. This information should help clinicians to anticipate palliative care needs of these patients, for example, recognising that higher starting doses of opioids and sedatives may help reduce prevalence and severity of breathlessness and agitation near death.